In a study of the Group III medulloblastoma cell line D283 (218), the HDACi inhibitor, sodium butyrate reduced cell viability, whereas the NMBR antagonist BIM-23127 had no effect on cell viability alone, in contrast to the GRPR antagonist RC-3095, which stimulated growth of these cells (218). Here, GRPR is linked to medulloblastoma.